BIOA – bioage labs, inc. (US:NASDAQ)
Stock Stats
News
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
BioAge Labs (NASDAQ:BIOA) was upgraded by analysts at Wall Street Zen
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
BioAge Labs (NASDAQ:BIOA) was downgraded by analysts at Wall Street Zen<
BLA for subcutaneous formulation of Leqembi® accepted in China
Form 4 BioAge Labs, Inc. For: Jan 13 Filed by: GOLDSTEIN DOV A MD
Form 4 BioAge Labs, Inc. For: Jan 13 Filed by: Fortney Kristen
Form 144 BioAge Labs, Inc. Filed by: Fortney Kristen
Form 144 BioAge Labs, Inc. Filed by: GOLDSTEIN DOV A MD
Form 8-K BioAge Labs, Inc. For: Jan 12
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.